Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784 is registered in ClinicalTrials.gov with Palo Alto Veterans Institute for Research as lead sponsor.

NCT NCT02500784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
Lead sponsor
Palo Alto Veterans Institute for Research
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2023
Completion date
July 31, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, cognitive dysfunction